Patients With MS on DMT Should Receive COVID-19 Booster, Study Says
The disease-modifying therapy (DMT) cladribine does not compromise the development of a specific humoral response in patients with multiple sclerosis (MS), according to a new study published in Multiple Sclerosis and Related Disorders. “For ocrelizumab and fingolimod, a significant [antibody] response can be achieved with further vaccinations,” the authors of the study wrote. These findings…